The Double Edged Spoon: Weight Loss Drugs and Their Broader Implications The FDA's approval of Eli Lilly's Mounjaro for reducing cardiovascular risks in high risk type 2 diabetes patients marks a significant milestone in the development of GLP 1 drugs.
These medications, which include Novo Nordisk's Wegovy, have been touted as game changers for weight loss and associated health issues.
But as their use expands beyond obesity treatment, it's essential to consider the broader implications of these treatments.